Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical safety follow-up after BGG492 exposure in partial onset seizures
2013-003431-29Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selurampanel in Focal Onset Epilepsy, sponsored by Novartis. Primary endpoint: Clinically significant findings of adrenal cortical adenomas and uterine endometrial stromal sarcomas. Started Apr 2014; status: completed.
02
Drugs
selurampanel
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2013-003431-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003431-29.